Radioactive iodine therapy: multiple faces of the same polyhedron

ABSTRACT The incidence of differentiated thyroid carcinoma (DTC) has increased in recent decades with early stage, low risk papillary thyroid cancer (PTC) being detected and diagnosed. As a result, the psychological, financial, and clinical ramifications of overdiagnosis and excessively aggressive therapy are being increasingly recognized with many authorities calling for a re-evaluation of the traditional “one size fits all” management approaches. To address these critical issues, most thyroid cancer guidelines endorse a more risk adapted management strategy where the intensity of therapy and follow up is matched to the anticipated risk of recurrence and death from DTC for each patient. This “less is more” strategy provides for a minimalistic management approach for properly selected patients with low-risk DTC. This has re-kindled the long-standing debate regarding the routine use of radioactive iodine therapy (RIT) in DTC. Although recent guidelines have moved toward a more selective use of RIT, particular in patients with low-intermediate risk DTC, the proper selection of patients, the expected benefit, and the potential risks continue to be a source of ongoing controversy and debate. In this manuscript, we will review the wide range of clinical, imaging, medical team, and patient factors that must be considered when evaluating individual patients for RIT. Through a review of the current literature evaluating the potential benefits and risks of RIT, we will present a risk adapted approach to proper patient selection for RIT which emphasizes peri-operative risk stratification as the primary tool that clinicians should use to guide initial RIT management recommendations.

Saved in:
Bibliographic Details
Main Authors: Padovani,Rosália do Prado, Chablani,Sumedha V., Tuttle,Robert Michael
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Endocrinologia e Metabologia 2022
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000300393
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2359-39972022000300393
record_format ojs
spelling oai:scielo:S2359-399720220003003932022-08-12Radioactive iodine therapy: multiple faces of the same polyhedronPadovani,Rosália do PradoChablani,Sumedha V.Tuttle,Robert MichaelABSTRACT The incidence of differentiated thyroid carcinoma (DTC) has increased in recent decades with early stage, low risk papillary thyroid cancer (PTC) being detected and diagnosed. As a result, the psychological, financial, and clinical ramifications of overdiagnosis and excessively aggressive therapy are being increasingly recognized with many authorities calling for a re-evaluation of the traditional “one size fits all” management approaches. To address these critical issues, most thyroid cancer guidelines endorse a more risk adapted management strategy where the intensity of therapy and follow up is matched to the anticipated risk of recurrence and death from DTC for each patient. This “less is more” strategy provides for a minimalistic management approach for properly selected patients with low-risk DTC. This has re-kindled the long-standing debate regarding the routine use of radioactive iodine therapy (RIT) in DTC. Although recent guidelines have moved toward a more selective use of RIT, particular in patients with low-intermediate risk DTC, the proper selection of patients, the expected benefit, and the potential risks continue to be a source of ongoing controversy and debate. In this manuscript, we will review the wide range of clinical, imaging, medical team, and patient factors that must be considered when evaluating individual patients for RIT. Through a review of the current literature evaluating the potential benefits and risks of RIT, we will present a risk adapted approach to proper patient selection for RIT which emphasizes peri-operative risk stratification as the primary tool that clinicians should use to guide initial RIT management recommendations.info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArchives of Endocrinology and Metabolism v.66 n.3 20222022-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000300393en10.20945/2359-3997000000461
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Padovani,Rosália do Prado
Chablani,Sumedha V.
Tuttle,Robert Michael
spellingShingle Padovani,Rosália do Prado
Chablani,Sumedha V.
Tuttle,Robert Michael
Radioactive iodine therapy: multiple faces of the same polyhedron
author_facet Padovani,Rosália do Prado
Chablani,Sumedha V.
Tuttle,Robert Michael
author_sort Padovani,Rosália do Prado
title Radioactive iodine therapy: multiple faces of the same polyhedron
title_short Radioactive iodine therapy: multiple faces of the same polyhedron
title_full Radioactive iodine therapy: multiple faces of the same polyhedron
title_fullStr Radioactive iodine therapy: multiple faces of the same polyhedron
title_full_unstemmed Radioactive iodine therapy: multiple faces of the same polyhedron
title_sort radioactive iodine therapy: multiple faces of the same polyhedron
description ABSTRACT The incidence of differentiated thyroid carcinoma (DTC) has increased in recent decades with early stage, low risk papillary thyroid cancer (PTC) being detected and diagnosed. As a result, the psychological, financial, and clinical ramifications of overdiagnosis and excessively aggressive therapy are being increasingly recognized with many authorities calling for a re-evaluation of the traditional “one size fits all” management approaches. To address these critical issues, most thyroid cancer guidelines endorse a more risk adapted management strategy where the intensity of therapy and follow up is matched to the anticipated risk of recurrence and death from DTC for each patient. This “less is more” strategy provides for a minimalistic management approach for properly selected patients with low-risk DTC. This has re-kindled the long-standing debate regarding the routine use of radioactive iodine therapy (RIT) in DTC. Although recent guidelines have moved toward a more selective use of RIT, particular in patients with low-intermediate risk DTC, the proper selection of patients, the expected benefit, and the potential risks continue to be a source of ongoing controversy and debate. In this manuscript, we will review the wide range of clinical, imaging, medical team, and patient factors that must be considered when evaluating individual patients for RIT. Through a review of the current literature evaluating the potential benefits and risks of RIT, we will present a risk adapted approach to proper patient selection for RIT which emphasizes peri-operative risk stratification as the primary tool that clinicians should use to guide initial RIT management recommendations.
publisher Sociedade Brasileira de Endocrinologia e Metabologia
publishDate 2022
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000300393
work_keys_str_mv AT padovanirosaliadoprado radioactiveiodinetherapymultiplefacesofthesamepolyhedron
AT chablanisumedhav radioactiveiodinetherapymultiplefacesofthesamepolyhedron
AT tuttlerobertmichael radioactiveiodinetherapymultiplefacesofthesamepolyhedron
_version_ 1756441500007268352